Preclinical efficacy of the novel dual PI3K/mTOR inhibitor, BEZ235 compared with RAD001 in HER2+breast tumors

被引：0
|
作者：
De, Pradip K. R. [1 ]
Sun, Yuliang [1 ]
Dey, Nandini [1 ]
Leyland-Jones, Brian [1 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-4496
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4496
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
    Shoji, Keiko
    Oda, Katsutoshi
    Kashiyama, Tomoko
    Ikeda, Yuji
    Nakagawa, Shunsuke
    Sone, Kenbun
    Miyamoto, Yuichiro
    Hiraike, Haruko
    Tanikawa, Michihiro
    Miyasaka, Aki
    Koso, Takahiro
    Matsumoto, Yoko
    Wada-Hiraike, Osamu
    Kawana, Kei
    Kuramoto, Hiroyuki
    McCormick, Frank
    Aburatani, Hiroyuki
    Yano, Tetsu
    Kozuma, Shiro
    Taketani, Yuji
    PLOS ONE, 2012, 7 (05):
  • [2] Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer
    Dey, N.
    Wu, H.
    Sun, Y.
    De, P.
    Leyland-Jones, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S17 - S17
  • [3] Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Oda, K.
    Shoji, K.
    Nakagawa, S.
    Kashiyama, T.
    Ikeda, Y.
    Miyamoto, Y.
    Tanikawa, M.
    Kuramoto, H.
    Nishida, M.
    Hiraike-Wada, O.
    Yano, T.
    Kozuma, S.
    Taketani, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer
    Shoji, Keiko
    Oda, Katsutoshi
    Nakagawa, Shunsuke
    Ikeda, Yuji
    Kashiyama, Tomoko
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Kuramoto, Hiroyuki
    Hiraike-Wada, Osamu
    Yano, Tetsu
    Taketani, Yuji
    CANCER RESEARCH, 2011, 71
  • [5] Biomarker analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/RAD001
    Brannron, A. Rose
    Melisi, Davide
    Hummel, Jennifer
    Carbone, Carmine
    Frizziero, Melissa
    Cheung, Wing
    Patel, Parul
    Gallo, Jorge
    Tortora, Giampaolo
    Morrissey, Michael
    Chen, David
    CLINICAL CANCER RESEARCH, 2016, 22
  • [6] Activity of dual PI3K/mTOR inhibitor, NVP-BEZ235, and mTOR inhibitor, RAD001 (everolimus), in endometrial cancer cell lines.
    Shoji, K.
    Oda, K.
    Nakagawa, S.
    Ikeda, Y.
    Kuramoto, H.
    Nishida, N.
    Kawana, K.
    Yano, T.
    Kozuma, S.
    Taketani, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma
    Kirstein, Martha M.
    Boukouris, Aristeidis E.
    Pothiraju, Deepika
    Buitrago-Molina, Laura E.
    Marhenke, Silke
    Schuett, Jutta
    Orlik, Johanna
    Kuehnel, Florian
    Hegermann, Jan
    Manns, Michael P.
    Vogel, Arndt
    LIVER INTERNATIONAL, 2013, 33 (05) : 780 - 793
  • [8] The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines
    Herrera, Vivian Arrias
    Zeindl-Eberhart, Evelyn
    Jung, Andreas
    Huber, Rudolf Maria
    Bergner, Albrecht
    ANTICANCER RESEARCH, 2011, 31 (03) : 849 - 854
  • [9] Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma
    Meng, Wei
    Wang, Baocheng
    Mao, Weiwei
    Wang, Jiajia
    Zhao, Yang
    Li, Qifeng
    Zhang, Chenran
    Ma, Jie
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2019, 81 (01): : 93 - 102
  • [10] Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
    Yan Zhu
    Tiantian Tian
    Jianling Zou
    Qiwei Wang
    Zhongwu Li
    Yanyan Li
    Xijuan Liu
    Bin Dong
    Na Li
    Jing Gao
    Lin Shen
    BMC Cancer, 15
12345